The longitudinal interplay between negative and positive symptom trajectories in patients under antipsychotic treatment: A post hoc analysis of data from a randomized, 1-year pragmatic trial

BMC Psychiatry

Volumn 13, Issue , 2013, Pages

  Chen, Lei ^a   Johnston, Joseph A ^a   Kinon, Bruce J ^a   Stauffer, Virginia ^a   Succop, Paul ^b   Marques, Tiago R ^c   Ascher Svanum, Haya ^a  

^a ELI LILLY AND COMPANY   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Negative symptoms; Positive symptoms; Schizophrenia; Trajectory interplay

Indexed keywords

OLANZAPINE;

ADULT; ARTICLE; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NEGATIVE SYNDROME; OPEN STUDY; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SYMPTOM ASSESSMENT; TIME FACTORS; TREATMENT OUTCOME;

EID: 84888217265     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/1471-244X-13-320     Document Type: Article

References (49)

1. Tsuang MT, Lyons MJ, Faraone SV. Heterogeneity of schizophrenia. Conceptual models and analytic strategies. Br J Psychiatry 1990, 156:17-26. 10.1192/bjp.156.1.17, 2404538.
2. McGrath J. Dissecting the heterogeneity of schizophrenia outcomes. Schizophr Bull 2008, 34(2):247-248. 2632410, 18048379.
3. Case M, Stauffer VL, Ascher-Svanum H, Conley R, Kapur S, Kane JM, Kollack-Walker S, Jacob J, Kinon BJ. The heterogeneity of antipsychotic response in the treatment of schizophrenia. Psychol Med 2011, 41(06):1291-1300. 10.1017/S0033291710001893, 3080711, 20925971.
4. Levine SZ, Leucht S. Elaboration on the early-onset hypothesis of antipsychotic drug action: treatment response trajectories. Biol Psychiatry 2010, 68(1):86-92. 10.1016/j.biopsych.2010.01.012, 20227681.
5. Levine SZ, Rabinowitz J, Faries D, Lawson AH, Ascher-Svanum H. Treatment response trajectories and antipsychotic medications: examination of up to 18 months of treatment in the CATIE chronic schizophrenia trial. Schizophr Res 2012, 137(1-3):141-146.
6. Levine SZ, Rabinowitz J, Case M, Ascher-Svanum H. Treatment response trajectories and their antecedents in recent-onset psychosis: a 2-year prospective study. J Clin Psychopharmacol 2010, 30(4):446-449. 10.1097/JCP.0b013e3181e68e80, 20631562.
7. Levine SZ, Rabinowitz J. Trajectories and antecedents of treatment response over time in early-episode psychosis. Schizophr Bull 2010, 36(3):624-632. 10.1093/schbul/sbn120, 2879688, 18849294.
8. Levine SZ, Lurie I, Kohn R, Levav I. Trajectories of the course of schizophrenia: from progressive deterioration to amelioration over three decades. Schizophr Res 2011, 126(1-3):184-191.
9. First MB. Diagnostic and statistical manual of mental disorders 4th Ed. (DSM-IV-TR™, 2000), 4 edn 2000, American Psychiatric Association: Washington, DC.
10. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991, 148(10):1301-1308.
11. Buchanan RW, Breier A, Kirkpatrick B, Ball P, Carpenter WT. Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. Am J Psychiatry 1998, 155(6):751-760.
12. Kane JM, Marder SR, Schooler NR, Wirshing WC, Umbricht D, Baker RW, Wirshing DA, Safferman A, Ganguli R, McMeniman M, et al. Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison. Arch Gen Psychiatry 2001, 58(10):965-972. 10.1001/archpsyc.58.10.965, 11576036.
13. Kirkpatrick B, Fenton WS, Carpenter WT, Marder SR. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull 2006, 32(2):214-219. 10.1093/schbul/sbj053, 2632223, 16481659.
14. Levine BG, Stone JE, Kohlmeyer A. Fast analysis of molecular dynamics trajectories with graphics processing units-radial distribution function Histogramming. J Comput Phys 2011, 230(9):3556-3569. 10.1016/j.jcp.2011.01.048, 3085256, 21547007.
15. Lyne J, O'Donoghue B, Owens E, Renwick L, Madigan K, Kinsella A, Clarke M, Turner N, O'Callaghan E. Prevalence of item level negative symptoms in first episode psychosis diagnoses. Schizophr Res 2012, 135(1-3):128-133.
16. Addington J, Addington D. Positive and negative symptoms of schizophrenia. Their course and relationship over time. Schizophr Res 1991, 5(1):51-59. 10.1016/0920-9964(91)90053-T, 1854677.
17. Andreasen NC, Olsen SA, Dennert JW, Smith MR. Ventricular enlargement in schizophrenia: relationship to positive and negative symptoms. Am J Psychiatry 1982, 139(3):297-302.
18. Carpenter WT, Bartko JJ, Carpenter CL, Strauss JS. Another view of schizophrenia subtypes. A report from the international pilot study of schizophrenia. Arch Gen Psychiatry 1976, 33(4):508-516. 10.1001/archpsyc.1976.01770040068012, 938187.
19. Andreasen NC. Negative symptoms in schizophrenia. Definition and reliability. Arch Gen Psychiatry 1982, 39(7):784-788. 10.1001/archpsyc.1982.04290070020005, 7165477.
20. Cuesta MJ, Peralta V. Current psychopathological issues in psychosis: towards a phenome-wide scanning approach. Schizophr Bull 2008, 34(4):587-590. 2632449, 18483012.
21. Goghari VM, Sponheim SR, MacDonald AW. The functional neuroanatomy of symptom dimensions in schizophrenia: a qualitative and quantitative review of a persistent question. Neurosci Biobehav Rev 2010, 34(3):468-486. 10.1016/j.neubiorev.2009.09.004, 2813961, 19772872.
22. Guelfi GP, Faustman WO, Csernansky JG. Independence of positive and negative symptoms in a population of schizophrenic patients. J Nerv Ment Dis 1989, 177(5):285-290. 10.1097/00005053-198905000-00006, 2651558.
23. Javitt DC. Twenty-five years of glutamate in schizophrenia: are we there yet?. Schizophr Bull 2012, 38(5):911-913. 10.1093/schbul/sbs100, 3446216, 22987849.
24. Tunis SL, Faries DE, Nyhuis AW, Kinon BJ, Ascher-Svanum H, Aquila R. Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: results from a randomized, open-label, 1-year trial. Value Health 2006, 9(2):77-89. 10.1111/j.1524-4733.2006.00083.x, 16626411.
25. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987, 13(2):261-276. 10.1093/schbul/13.2.261, 3616518.
26. Kay SR, Opler LA, Lindenmayer JP. Reliability and validity of the positive and negative syndrome scale for schizophrenics. Psychiatry Res 1988, 23(1):99-110. 10.1016/0165-1781(88)90038-8, 3363019.
27. Santor DA, Ascher-Svanum H, Lindenmayer JP, Obenchain RL. Item response analysis of the positive and negative syndrome scale. BMC Psychiatry 2007, 7:66. 10.1186/1471-244X-7-66, 2211479, 18005449.
28. Cutler AJ, Kalali AH, Weiden PJ, Hamilton J, Wolfgang CD. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. J Clin Psychopharmacol 2008, 28(2 Suppl 1):S20-S28.
29. Kane JM, Assuncao-Talbott S, Eudicone JM, Pikalov A, Whitehead R, Crandall DT. The efficacy of aripiprazole in the treatment of multiple symptom domains in patients with acute schizophrenia: a pooled analysis of data from the pivotal trials. Schizophr Res 2008, 105(1-3):208-215.
30. Nakamura M, Ogasa M, Guarino J, Phillips D, Severs J, Cucchiaro J, Loebel A. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatry 2009, 70(6):829-836. 10.4088/JCP.08m04905, 19497249.
31. Muthen B, Muthen L. Mplus - Statistical analysis with latent variables - user's guide 2007, Muthen and Muthen: Los Angeles, 5.
32. Muthen B. Latent variable mixture modeling. New developments and techniques in structural equation modeling 2001, 1-33. Mahwah, NJ: Lawrence Erlbaum Associates, Marcoulides GA, Schumacker RE.
33. Bauer DJ, Curran PJ. Distributional assumptions of growth mixture models: implications for overextraction of latent trajectory classes. Psychol Methods 2003, 8(3):338-363.
34. Pearson WH. Estimation of a correlation coefficient from an uncertainty measure. Psychometrika 1966, 31(3):421-433. 10.1007/BF02289473, 5221136.
35. Gueorguieva R, Mallinckrodt C, Krystal JH. Trajectories of depression severity in clinical trials of duloxetine: insights into antidepressant and placebo responses. Arch Gen Psychiatry 2011, 68(12):1227-1237. 10.1001/archgenpsychiatry.2011.132, 3339151, 22147842.
36. Marques TR, Arenovich T, Agid O, Sajeev G, Muthen B, Chen L, Kinon BJ, Kapur S. The different trajectories of antipsychotic response: antipsychotics versus placebo. Psychol Med 2011, 41(7):1481-1488. 10.1017/S0033291710002035, 20961479.
37. Stauffer V, Case M, Kollack-Walker S, Ascher-Svanum H, Ball T, Kapur S, Kinon BJ. Trajectories of response to treatment with atypical antipsychotic medication in patients with schizophrenia pooled from 6 double-blind, randomized clinical trials. Schizophr Res 2011, 130(1-3):11-19.
38. Crow TJ. The two-syndrome concept: origins and current status. Schizophr Bull 1985, 11(3):471-486. 10.1093/schbul/11.3.471, 2863873.
39. Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III-the final common pathway. Schizophr Bull 2009, 35(3):549-562. 10.1093/schbul/sbp006, 2669582, 19325164.
40. Carpenter WT, Heinrichs DW, Wagman AM. Deficit and nondeficit forms of schizophrenia: the concept. Am J Psychiatry 1988, 145(5):578-583.
41. Tollefson GD, Sanger TM. Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. Am J Psychiatry 1997, 154(4):466-474.
42. Stauffer VL, Song G, Kinon BJ, Ascher-Svanum H, Chen L, Feldman PD, Conley RR. Responses to antipsychotic therapy among patients with schizophrenia or schizoaffective disorder and either predominant or prominent negative symptoms. Schizophr Res 2012, 134(2-3):195-201.
43. Kinon BJ, Kane JM, Chakos M, Munne R. Possible predictors of neuroleptic-resistant schizophrenic relapse: influence of negative symptoms and acute extrapyramidal side effects. Psychopharmacol Bull 1993, 29(3):365-369.
44. Chen J, Ascher-Svanum H, Nyhuis AW, Case MG, Phillips GA, Schuh KJ, Hoffmann VP. Reasons for continuing or discontinuing olanzapine in the treatment of schizophrenia from the perspectives of patients and clinicians. Patient Pref Adher 2011, 5:547-554.
45. Velligan DI, Alphs L, Lancaster S, Morlock R, Mintz J. Association between changes on the Negative Symptom Assessment scale (NSA-16) and measures of functional outcome in schizophrenia. Psychiatry Res 2009, 169(2):97-100. 10.1016/j.psychres.2008.10.009, 19664826.
46. Beasley CM, Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S. Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology (Berl) 1996, 124(1-2):159-167.
47. Beasley CM, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996, 14(2):111-123. 10.1016/0893-133X(95)00069-P, 8822534.
48. Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV, Avedisova AS, Bardenstein LM, Gurovich IY, Morozova MA, et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized phase 2 clinical trial. Nat Med 2007, 13(9):1102-1107. 10.1038/nm1632, 17767166.
49. Arango C, Buchanan RW, Kirkpatrick B, Carpenter WT. The deficit syndrome in schizophrenia: implications for the treatment of negative symptoms. Eur Psychiatry 2004, 19(1):21-26. 10.1016/j.eurpsy.2003.10.004, 14969777.